Business Context and Reporting Period
Company: Arvinas, Inc. (ARVN)
Filing Type: Form 8-K (Current Report)
Date of Report: May 11, 2026
Event: Entry into a Material Definitive Agreement (License Agreement) with Rigel Pharmaceuticals, Inc. regarding the asset VEPPANU (vepdegestrant).
Key Financial Metrics and Transaction Terms
This filing details a strategic licensing transaction rather than standard periodic financial results. Key financial terms include:
- Upfront Payment: $70.0 million aggregate (split evenly between Arvinas and Pfizer).
- Transition Payment: $15.0 million aggregate upon completion of select development and manufacturing transition activities.
- Development Contribution: Rigel to contribute up to $40.0 million towards ongoing development activities.
- Contingent Milestones: Up to $320.0 million aggregate based on future development, regulatory, and commercial milestones.
- Royalties: Tiered royalties in the mid-teens to mid-20s on worldwide net sales of VEPPANU.
- Revenue Sharing: Arvinas and Pfizer will share a percentage of sublicensing revenue generated outside the U.S.
Note: The filing does not provide current revenue, profit, cash flow, margins, debt, or liquidity metrics for the company.
Material Changes and Strategic Shifts
Commercialization Rights Transfer: Arvinas and Pfizer have granted Rigel exclusive global development, manufacturing, and commercialization rights for VEPPANU. Rigel will lead the U.S. launch and holds global rights with the ability to sublicense outside the U.S.
Operational Roles: Arvinas and Pfizer retain responsibility for current ongoing development activities, while Rigel assumes responsibility for launch and commercialization.
Contractual Replacement: The milestones and royalty payments under this new agreement replace any unearned future amounts previously owed by Pfizer to Arvinas under their July 21, 2021 collaboration agreement.
Outlook, Risks, and Contingencies
Closing Conditions: The transaction is subject to customary closing conditions, including the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
Termination Provisions:
- Rigel may terminate for material breach by Arvinas/Pfizer.
- Arvinas/Pfizer may terminate for material breach by Rigel.
- Rigel may terminate for convenience following a pre-defined period and written notice.
Risks: Forward-looking statements highlight risks regarding the satisfaction of closing conditions, performance obligations, and the ability of Rigel to successfully commercialize VEPPANU on expected timelines.
Investor Verification Checklist
- Verify the satisfaction of Hart-Scott-Rodino antitrust waiting period conditions for the deal to close.
- Confirm the specific split of the $70.0 million upfront payment and subsequent milestone payments between Arvinas and Pfizer.
- Monitor the filing of the full License Agreement text as an exhibit to the Form 10-Q for the quarter ending June 30, 2026.
- Assess the impact of the $40.0 million development contribution from Rigel on Arvinas's future cash burn and runway.
- Review the specific definitions of "mid-teens to mid-20s" royalty tiers and reduction circumstances in the full agreement.